Editorial Article
Nobody Has Ever Published a Reference Method for Allergen Testing, and That Is Why a Test Costs the Same in 2033 as It Did in 2025
The number that should not be possible
Global food allergen testing and control adds USD 1.00 billion of value between 2025 and 2033. Of that, USD 1,015 million — 101.5 per cent — is more tests. Price and mix subtract USD 15 million. A single allergen test is worth USD 16.50 at the start of the period and USD 16.39 at the end: 0.68 per cent cheaper across eight years.
Put that beside almost any other food testing market and it reads as an error. In the global food safety testing market measured in the same way, price carried 25.1 per cent of growth. In most industrial markets price carries a third to a half. Here it carries minus one and a half per cent, and the explanation is not commoditisation, or a demand shock, or a price war. It is that allergen testing has never had a reference method.
What a reference method actually does to a price
When a regulator publishes a method, three things happen at once. The method becomes the thing a laboratory must buy equipment for, train staff against and accredit to. The result becomes comparable between laboratories, which makes it admissible. And the cost of deviating becomes commercial rather than technical, because a laboratory that invents its own procedure has to explain the deviation to every customer who audits it.
Pathogen testing works exactly this way. Salmonella detection has a defined enrichment, a selective medium and a confirmation step; a laboratory that departs from them takes a commercial risk it rarely chooses to take. That structure is what stops the price of a pathogen test collapsing: you are not selling an answer, you are selling the answer, and there is only one of those.
Allergen testing has nothing equivalent anywhere in the world. There is no internationally mandated procedure for detecting peanut protein in a biscuit, and the reason is analytical rather than political. What is being measured is a protein class, not an organism. A protein class behaves differently in every matrix it is baked, fermented, hydrolysed or extruded into. A method validated on spiked flour tells you less than you would like about a chocolate bar.
So a laboratory chooses. It can choose any validated commercial kit, and validation in the absence of a certified reference material means validating against a matrix it prepared itself. That is a defensible position, and it is also the definition of a market with no price floor.
The three constraints the literature names
The method literature is unusually candid about this. A 2026 systematic review of analytical methods for gluten detection names the recurring constraints as the lack of certified reference materials, methodological variation among laboratories, and difficulty extracting the target efficiently from complex matrices.
Read those three together and you have a specification for a commodity. If two laboratories can both be right while producing different numbers, the buyer’s rational response is to buy on price, because the analytical difference cannot be inspected. That is why the price of an allergen test does nothing across eight years.
| Period | Value effect of more tests | Value effect of price and mix | Total change | Volume share | Price share |
|---|---|---|---|---|---|
| 2025–2028 | +USD 371m | −USD 71m | +USD 300m | 123.8% | −23.8% |
| 2028–2033 | +USD 614m | +USD 86m | +USD 700m | 87.7% | 12.3% |
| 2025–2033 | +USD 1,015m | −USD 15m | +USD 1,000m | 101.5% | −1.5% |
The four-plex problem
The second force is multiplexing, and it is best seen in a single catalogue item. R-Biopharm’s four-plex cereals kit separates wheat, barley and rye in one well. Three analyte decisions, one consumable event, one sample preparation.
That is a better product and a smaller revenue event. The buyer’s cost per decision falls sharply; the seller’s revenue per sample falls too; and the buyer’s number of answerable questions rises. This is genuine productivity, and in a market with no reference method and no certified material it gets competed away rather than retained.
So the eight-year aggregate hides a movement. Split the series at 2028 and the two effects swap roles. Between 2025 and 2028 value per test falls from USD 16.50 to USD 15.74, and price subtracts 23.8 per cent of the growth. Between 2028 and 2033 value per test recovers to USD 16.39 and price adds 12.3 per cent.
What happened in July 2026
The recovery is not a forecast of better pricing discipline. It is the consequence of a specific regulatory event. In July 2026 the Codex Alimentarius Commission adopted guidelines on precautionary allergen labelling as an annex to the General Standard for the Labelling of Pre-packaged Foods, with 21 reference doses — 1.0 milligram of total protein for almond, cashew, celery and mustard, up to 200.0 milligrams for crustacea — and 4.0 milligrams of gluten for coeliac disease.
The action level is the reference dose divided by the amount of food reasonably consumed on a single eating occasion. A “may contain” statement is justified above that level and, crucially, should not be used below it.
That second clause is what changes the price. Detecting presence does not answer an action level. Neither does a lateral flow device whose limit of detection sits above it. What answers it is a calibrated quantitative method — a sandwich or competitive ELISA with a validated standard curve, or LC-MS/MS — and quantification is priced above a qualitative screen.
| Measure | 2025 | 2028 | 2033 |
|---|---|---|---|
| Tests run, million | 71.5 | 94.0 | 133.0 |
| Value per test, USD | 16.50 | 15.74 | 16.39 |
| Market value, USD billion | 1.18 | 1.48 | 2.18 |
| Of which control layer, USD million | 105 | 155 | 320 |
Who wins when the price never moves
Two business models are exposed to the same demand and to opposite risks. Neogen, R-Biopharm, Romer Labs, Thermo Fisher Scientific and Bio-Rad Laboratories sell consumables and are exposed to tests run. Eurofins Scientific, SGS, Bureau Veritas, Intertek Group and Mérieux NutriSciences sell capacity and are exposed to samples sent out.
In a market where a lateral flow device at the line costs single-digit dollars and a send-out costs tens, the consumable side wins the volume. The laboratory side wins the price, because quantification is what it is selling after 2028, and quantification carries the documentation the annex requires.
The disclosed evidence supports the split. Neogen’s fiscal 2026 Form 10-K reports Natural Toxins and Allergens at USD 77.5 million, up 0.6 per cent — while its Bacterial and General Sanitation line grew 6.4 per cent to USD 175.4 million. Eurofins’ first-half 2026 report shows Food and Feed Europe delivering mid-single-digit organic growth. The party selling the bundle is collecting growth the party selling the part is not.
What would change this answer
Only one variable does enough work to move the conclusion, and it is value per test. Hold tests at 133.0 million in 2033 and move the price of a test to USD 14.50 — the case where multiplex compounds and the quantitative premium never arrives — and the market is USD 1,928 million, growing at 6.33 per cent. Move it to USD 16.80 as the documentation layer becomes a priced service line, and it is USD 2,234 million at 8.31 per cent.
That spread is a regulatory bet, not a commercial one. The base case sits closer to the bull than the midpoint because the regulatory events have already happened: the annex was adopted, the European harmonisation timetable exists, and the FDA convened a threshold meeting in February 2026. What is uncertain is the speed of transposition, not its direction.
Until then the structural fact holds. A market with no reference method cannot protect the price of its own answer, and it will grow by doing more of the same thing rather than by doing it better. The companies that understand this are investing in the test count, not in the test price — and the ones that will earn from the change are selling the paperwork that finally makes the number mean something. The full analysis sits in the Food Allergen Testing & Control market report, alongside the Food Safety and Quality Testing segment it belongs to.
References
- Codex Committee on Food Labelling, 49th session. Annex to CXS 1-1985: Guidelines on the use of precautionary allergen labelling, reference dose tables 4.3.1 and 4.3.2. FAO/WHO.
- Codex Alimentarius Commission, July 2026. Adoption of the precautionary allergen labelling guidelines at CAC49.
- Quirino Junior et al., Food Reviews International, 2026. Strategies and analytical methods for the detection and quantification of gluten in foods: a systematic review.
- Neogen Corporation. Form 10-K for the fiscal year ended 31 May 2026; fourth-quarter and full-year fiscal 2026 results, 30 July 2026.
- Eurofins Scientific. First-half 2026 report, 23 July 2026.
- R-Biopharm. Allergen and gluten testing portfolio documentation, including SureFood ALLERGEN four-plex cereals.
Frequently Asked Questions
Why is the price of an allergen test flat while other food testing markets see prices rise?
Because allergen testing has no statutory reference method anywhere in the world. A pathogen test is pinned to a published procedure, which becomes the thing a laboratory must accredit to and makes results comparable between laboratories. An allergen test can be run on any validated commercial kit, and in the absence of certified reference materials validation is against a matrix the laboratory prepared itself. Where the method is free, the price is free with it.
What is the value per test in this market?
USD 16.50 in 2025, falling to USD 15.74 in 2028 and recovering to USD 16.39 by 2033 — a net decline of 0.68 per cent across eight years. The trough in 2028 is where multiplex panels compress analyte-level pricing fastest; the recovery after 2028 comes from Codex action levels forcing quantified results rather than yes-or-no detection.
How does multiplexing reduce revenue per test?
A four-plex kit that separates wheat, barley and rye in a single well performs three analyte decisions in one consumable event. The buyer's cost per decision falls, the seller's revenue per sample falls, and the buyer's number of answerable questions rises. It is genuine productivity gain, and in a market with no reference method it gets competed away rather than retained by the seller.
Which companies are most exposed to a flat unit price?
The consumable vendors — Neogen, R-Biopharm, Romer Labs, Thermo Fisher and Bio-Rad — earn margin per test and are exposed to tests run. The laboratory networks — Eurofins, SGS, Bureau Veritas, Intertek and Mérieux NutriSciences — earn utilisation on capacity and are exposed to samples sent out. As screening migrates to lateral flow at the line, consumable revenue grows faster than send-out revenue, and the laboratories capture the price recovery because quantification is what they sell after 2028.
